Experimental Safety Switch Has Potential to Reduce CAR T Side Effects

March 11th 2021, 9:15pm


An experimental safety switch incorporated into chimeric antigen receptor (CAR) T-cell therapy reduced the severity of the treatment’s side effects in an early-phase trial.

Targeted PRO Tools Needed to Evaluate QOL in Immuno-Oncology Trials

March 5th 2021, 10:15pm


A review published in Cancer examines the efficacy and drawbacks of tools used to evaluate health-related quality of life in immuno-oncology clinical trials.

Circulating T Cells Provide Insight on Tumor Sister Cells in Advanced Melanoma

March 5th 2021, 6:00pm


A new study found that performing single-cell RNA sequencing on T cells circulating in the blood provided significant insight on sister cells within tumor tissue in advanced melanoma.

ASH 2020: CAR T-Cell Therapy Updates

January 20th 2021, 6:45pm


Exciting new and ongoing developments in chimeric antigen receptor (CAR) T-cell therapies were covered at the 62nd American Society of Hematology (ASH) annual meeting.

Drug That Boosts Immunotherapy Studied as Tool to Battle COVID-19 in Patients With Cancer

October 30th 2020, 4:00am


An investigational drug, IMM-101, already being studied for its ability to increase the effects of immuno-oncology agents, may be able to prevent or lessen the effects of COVID-19 among those with cancer.

Best Cancer Tests Don't Reach All Who Need Them

August 17th 2020, 9:15am


Evidence-Based Oncology managed care updates for August 2020 feature coverage of liquid biopsies, companion diagnostics, and CAR T-cell therapy.

The Promise of Specialty Oncology Innovations in the Drug Pipeline

May 1st 2019, 7:11pm


The oncology drug pipeline has experienced rapid growth over the past decade, driven by innovation in cell therapies, immunotherapy, and precision medicine, according to a specialty pipeline update presentation at Asembia's 15th annual Specialty Pharmacy Summit, held April 29 to May 2 in Las Vegas.

Dr Lee Schwartzberg Reflects on the Approval of the First Immunotherapy Regimen in Breast Cancer

April 12th 2019, 5:00pm


The breast cancer community is very excited about the approval of atezolimuab for the treatment of triple-negative breast cancer, explained Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.

Cost Differential of Immuno-Oncology Therapy Delivered at Community Versus Hospital Clinics

March 7th 2019, 10:00pm


Administration of immuno-oncology therapy for cancer diagnoses in the community clinic setting is associated with lower costs compared with administration in a hospital-based clinic setting.

This Week in Managed Care: February 15, 2019

February 15th 2019, 7:23pm


This week, the top managed care news included increased demand for long-acting contraception since President Trump took office; a payer decision on an insulin pump alarmed diabetes advocates; and despite being involved in cancer treatment decisions, many primary care providers don't feel prepared to do so.